Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Neuroendocrine Cancer: Drugs

Department of Health written question – answered on 7th June 2016.

Alert me about debates like this

Photo of Nick Brown Nick Brown Chair, Finance Committee (Commons)

To ask the Secretary of State for Health, with reference to findings presented at the 2015 European Cancer Congress on Lutathera, what assessment he has made of the reported benefits of that drug on treating patients with neuroendocrine tumours.

Photo of George Freeman George Freeman The Parliamentary Under-Secretary of State for Business, Innovation and Skills, The Parliamentary Under-Secretary of State for Health

The clinical research findings on Lutathera, presented to the European Cancer Congress, have not yet been published in a peer-reviewed journal.

The National Institute for Health and Care Excellence (NICE) has been asked to develop technology appraisal guidance on lutetium-177 dotatate for the treatment of unresectable, somatostatin receptor-positive, gastroenteropancreatic neuroendocrine tumours. NICE’s guidance is based on a thorough assessment of the available evidence and is developed through wide consultation with stakeholders.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.